Co-Investigator in the multicentric studies 

• A 3 year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior Segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with diabetic macular edema. 
• A randomized, double masked , active controlled phase 3 study of the efficacy, safety and tolerability of repeteated doses of intravitreal VEGF trap-Eye in subjects with neovascular age-related macular degeneration (AMD) (VIEW2). 
• A phase II  prospective , randomised , multicentric diabetic macular edema  dose ranging, comparation study evaluating the efficacy and safety of PF- 04523655 versus laser therapy (DEGAS). 
• A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO) (GALILEO). 
• Macular edema Incidence/Severity Reduction with NEVANAC®. Phase IIIb, prospective, multicenter, double-masked, randomized, parallel group, placebo controlled study. 
• Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema (RETAIN). 
• Multicentric, phase 3, randomized, double blind, active control, 12 months follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab vs photodynamic therapy in myopic CNV. 
• A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema (VIVID). 
• A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in Patients with Branch Retinal Vein Occlusion (COMO). 
• A multicenter, open-label, randomized study comparing the efficacy and safety of 700 mg Dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema. 
• Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy. (PROTEUS). 
• A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) (MINERVA). 
• A 12 months, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Novartis. 
• A 12-month, phase IIIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular agerelated macular degeneration (TREND). 
• A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration (FOVISTA). 
• Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration (DARPin) Allergan. 
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY OF EFFICACY AND SAFETY OF 10 mg LAMPALIZUMAB INTRAVITREAL INJECTIONS ADMINISTERED EVERY 30 OR 45 DAYS TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.